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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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MONDAY, DECEMBE R 11, 2017

Ionis drug successfully reduces toxic Huntington’s
disease protein, paving way for Phase 2 trial of effect
on patients
In an initial clinical trial that marks a significant step toward finding an
effective Huntington’s disease treatment, the Ionis Pharmaceuticals genesilencing drug safely reduced the production of the toxic mutant protein
implicated in HD, the firm announced today.
Ionis has handed development of the expected Phase 2 trial to its partner
in the project, the multinational pharmaceutical giant Roche, earning a
$45 million license fee, today’s Ionis press release stated. The drug is
called IONIS-HTTRx: “HTT” stands for both the huntingtin gene and the
protein it produces, and “Rx” signifies a remedy.
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The trial was officially classified as Phase 1/2a. A Phase 1 trial measure’s a
drug’s safety and tolerability in a small number of participants, while a
Phase 2 trial examines efficacy in a larger group of patients. Though
mainly Phase 1, this trial had elements of a Phase 2: actual HD patients
took part, and it sought to determine whether the drug’s basic mechanism
worked.
“We are encouraged by the performance of IONIS-HTTRx in the Phase
1/2a clinical study,” Frank Bennett, Ph.D., Ionis senior vice president of
research, stated in the release.
The reductions of the mutant protein “observed in the study substantially
exceeded our expectations,” Dr. Bennett added. The study, which involved
46 participants with early HD symptoms, did not assess whether that
reduction slowed disease progression.
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Ionis stated that “dose-dependent reductions of mHTT were observed” in
the trial: the higher the dosage, the greater the reduction in the amount of
the mutant protein.
“We were equally encouraged by the safety profile of the drug,” Dr.
Bennett stated.
“The results of this trial are of ground-breaking importance for
Huntington’s disease patients and families,” stated Dr. Sarah Tabrizi,
professor of clinical neurology, director of the University College London’s
Huntington Centre, and the global lead investigator on the Phase 1/2a
study. “For the first time, a drug has lowered the level of the toxic diseasecausing protein in the nervous system, and the drug was safe and well
tolerated. The key now is to move quickly to a larger trial to test whether
IONIS-HTTRx slows disease progression.”
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Frank Bennett, Ph.D. (above, photo by Kristina Bowyer, Ionis) and Dr.
Sarah Tabrizi (below, photo by Gene Veritas)

Pharma giant Roche steps in
Ionis officials stated in June that a Phase 2 study could start as soon as
2018. Typically, all three phases of a clinical trial project take at least five
years, although nobody can predict the actual course of a trial.
In 2013, Ionis, a mid-sized drug-discovery firm that does not produce or
sell drugs or conduct clinical trials on its own, partnered with Roche, one
of the world’s largest and most successful pharmaceutical companies (click
here and here to read more). Roche’s expertise includes neurodegenerative
brain diseases.
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Roche will now take over the development of IONIS-HTTRx, including the
Phase 2 and potential Phase 3 trials and bringing the drug to market. It
will hold the license to the drug.
Roche also will administer the open-label extension of the Phase 1/2a
study, announced in June, whereby all patients – including those who got
a placebo – will continue to receive the drug. The extension allows
researchers to gather more data, examine the drug’s effects over a longer
period of time, and better prepare for Phase 2. Patients also potentially
benefit by receiving the drug longer.
Phase 2 to include United States
By attacking Huntington’s disease near its genetic roots, IONIS-HTTRx
could potentially reduce, partly reverse, and even prevent symptoms. Ionis
drugs are antisense oligonucleotides, artificial strands of DNA. The drug
aims to turn off the huntingtin gene messenger RNA that contains the
instructions to make the huntingtin protein in brain cells.
Forty-six patients took part in the Phase 1/2a trial at sites in Canada,
Germany, and England.
“Today is an exciting day for the Huntington’s disease community,” a joint
Ionis-Roche letter to the HD community stated. “Future studies for the
program will be conducted globally, including in the U.S. Roche will
announce details about future studies, including eligibility criteria and
planned start dates, as this information becomes available.”
More than a decade of research
IONIS-HTTRx resulted from more than a decade of research involving
Ionis, Roche, the lab of neurobiologist Donald Cleveland, Ph.D., at the
University of California, San Diego, and CHDI Foundation, Inc., the
nonprofit virtual biotech firm aimed solely at finding (and funding) HD
treatments.
On December 3, Dr. Cleveland received the $3 million Breakthrough Prize,
the world’s richest science award, sponsored by Google, Facebook, and
other entities. It is twice the value of the Nobel Prize. Dr. Cleveland
received recognition for his career contributions to the life sciences,
including work on a cause of Alzheimer’s disease. (Click here to read
more.)
Dr. Cleveland was honored at the 2012 gala of the San Diego Chapter of
the Huntington’s Disease Society of America. For a recent article
explaining the Dr. Cleveland’s role in the Ionis project, click here.
In interviews today, I hope to obtain further details about the progress
regarding IONIS-HTTRx.
HDBuzz’s take: a historic breakthrough
The HD research site HDBuzz, produced by scientists, stated that today’s
announcement is “likely to stand as one of the biggest breakthroughs in
Huntington’s disease since the discovery of the HD gene in 1993.”
The site’s article, written by Jeff Carroll, Ph.D. – an HD-gene carrier like
me and a scientist dedicating his career to finding HD treatments –
asserted that the “most exciting” part of today’s news is that “dosedependent reductions of mutant huntingtin were observed.”
The clinical trial administrators know this because they examined samples
of participants’ cerebrospinal fluid, which runs along the spine and into
curehd.blogspot.com/2017/12/ionis-drug-successfully-reduces-toxic.html
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the brain. Participants received injections of the drug via a spinal tap.
“This means that patients treated with IONIS-HTTRx have reductions in
the huntingtin protein in their cerebrospinal fluid,” Dr. Carroll wrote.
“Based on this result, it looks like the drug is doing what it’s meant to do,
and that huntingtin lowering has been achieved!”
Dr. Wild concluded: “This is a great day in the HD community, and it sets
us on the path to even more exciting work in 2018. For the first time in
history, HD patients are being treated with drugs known to reduce the
amount of huntingtin protein in their brain. Until we conduct the next
trial, we won’t know if this reduces the impact of HD. And while we know
the drug is safe in the short term, we will also have to watch carefully for
any long-term adverse effects. But we’re facing this problem with renewed
excitement and hope. It’s the best early Christmas present we could have
hoped for.”

Jeff Carroll, Ph.D., at the 2012 CHDI-sponsored HD therapeutics conference
(photo by Gene Veritas)
(Disclosure: I hold a symbolic amount of Ionis shares.)
Posted by Gene Veritas at 7:28 AM
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1 comment:
Anonymous said...
So hopeful. Thanks.
6:18 PM, December 13, 2017
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